These differences may be due to the characteristics of the markers, evaluation methods, and/or cohorts (e.g., patient number and stage): CEA is aberrantly expressed by neoplastic cells and detected by serum chemiluminescent immunoassay; the decreased or lost expression of SPATA18 in tumor cells was evaluated by immunohistochemistry. Here, CEACAM5 is linked to neoplasm.